LON:TILS Tiziana Life Sciences (TILS) Share Price, News & Analysis → Emergency: Biden's $20 Trillion Mistake Could Cost YOU! (From GoldenCrest Metals) (Ad) Free TILS Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range 58.50▼ 58.5052-Week Range N/AVolume297,127 shsAverage Volume522,223 shsMarket Capitalization£113.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Tiziana Life Sciences alerts: Email Address Ad GoldenCrest MetalsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.Learn More Now About Tiziana Life Sciences Stock (LON:TILS)Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. The company also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. It has a collaboration agreement with FHI Clinical Inc. to conduct a phase 2 clinical trial for treating hospitalized severe COVID-19 patients with intranasal foralumab, a human anti-CD3 monoclonal antibody. The company was incorporated in 1998 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.Read More Ad GoldenCrest MetalsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.Learn More Now TILS Stock News HeadlinesApril 17, 2024 | americanbankingnews.comTiziana Life Sciences (LON:TILS) Shares Cross Below 200-Day Moving Average of $58.50December 6, 2023 | proactiveinvestors.comTiziana Life Sciences to present immunotherapy updates at...Tiziana Life Sciences to present immunotherapy updates at Webull...April 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.October 18, 2023 | markets.businessinsider.comTiziana : FDA Allows Multiple Sclerosis Patients To Take Home & Self-administer Intranasal ForalumabOctober 18, 2023 | proactiveinvestors.comTiziana Life Sciences: FDA signs off on home-based protocol fo MS treatmentOctober 16, 2023 | markets.businessinsider.comTiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal ForalumabOctober 13, 2023 | proactiveinvestors.comTiziana Life Sciences reports six-month PET scan results for MS patientsSeptember 26, 2023 | uk.investing.comTiziana Life Sciences Ltd (0RP)April 24, 2024 | GoldenCrest Metals (Ad)Emergency: Biden's $20 Trillion Mistake Could Cost YOU!The stakes have never been higher for your savings. Here's the hard truth: A banking crisis is looming. Your money is in the crosshairs of a $20 trillion commercial loan debt disaster, set to erupt.September 26, 2023 | tmcnet.comTiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple SclerosisAugust 23, 2023 | technews.tmcnet.comTiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of NeuroimmunologyAugust 15, 2023 | msn.comTiziana Life Sciences’ stock soars 54% premarket after FDA clear path for trial of intranasal treatment for Alzheimer’s diseaseApril 21, 2023 | benzinga.comTiziana Life Sciences To Submit Alzheimer's IND In Q2 2023, Seeks $3 Million From An Alzheimer's Foundation To Support Phase 2a TrialMarch 19, 2023 | seekingalpha.comTiziana Life Sciences CEO purchases sharesSeptember 25, 2022 | finanznachrichten.deTiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical OfficerSeptember 9, 2022 | benzinga.comTiziana Life Sciences Announces Purchase of Common Shares by Chief Medical OfficerSeptember 6, 2022 | yahoo.comHarry Styles and Olivia Wilde Hit Their First Red Carpet Together Amid 'Don't Worry Darling' DramaJuly 2, 2022 | proactiveinvestors.comTiziana Life Sciences' half-term report reveals it has made progress on all frontsJune 17, 2022 | finance.yahoo.comTiziana Life Sciences Ltd. Receives Nasdaq Deficiency NoticeJune 9, 2022 | fool.co.ukTiziana Life SciencesJune 8, 2022 | benzinga.comProactive news headlines including NEO Battery Materials, New Age Metals, Belmont Resources, Ridgeline Minerals, Electra Battery Materials, Tiziana Life Sciences and Aben ResourcesJune 8, 2022 | benzinga.comTiziana Life Sciences Shares Jump After Multiple Sclerosis Data From Second PatientJune 7, 2022 | investing.comAdvan Co Ltd (7463)May 21, 2022 | dailymail.co.ukSilvio Berlusconi, 85, 'used women as sex slaves' at his infamous 'bunga bunga' parties during time as Italian PM and was a 'sultan in his own harem', court hearsApril 5, 2022 | financialpost.comProactive news headlines including SPYR, Predictmedix, Bridgeline Digital, Tiziana Life Sciences, GameSquare and Empower ClinicsMarch 24, 2022 | proactiveinvestors.comTiziana Life Sciences: Multiple Sclerosis single studyMarch 24, 2022 | proactiveinvestors.comTiziana Life Sciences: Method of therapy delivery gives firm 'a novel market position'See More Headlines Receive TILS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/30/2020Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:TILS Previous SymbolLON:ADI CUSIPN/A CIKN/A Webwww.tizianalifesciences.com Phone+44-20-74952379FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio2.36 Current Ratio6.54 Quick Ratio6.41 Sales & Book Value Annual Sales£-3,595,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.28 Book ValueGBX 23.50 per share Price / BookN/AMiscellaneous Outstanding Shares194,612,000Free FloatN/AMarket Cap£113.85 million OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Gabriele Marco Antonio Cerrone M.B.A. (Age 49)MBA, Founder & Exec. Chairman Comp: $13.76MDr. Kunwar Shailubhai (Age 63)CEO, Chief Scientific Officer & Exec. Director Comp: $810kDr. Andrea BrancaleScientific FounderMr. Richard Clarkson Ph.D.Scientific FounderMr. Andrew Westwell Ph.D.Scientific FounderMs. Keeren Shah (Age 44)Fin. Director Dr. Thomas H. Adams (Age 78)Head of Drug Devel. & Exec. Director Dr. Neil Graham M.P.H. (Age 62)MBBS, M.D., MPH, Chief Medical Officer Dr. Napoleone Ferrara (Age 63)Chairman of Scientific Advisory Board Prof. Roberto PellicciariConsultantMore ExecutivesKey CompetitorsVerseonLON:VSNFutura MedicalLON:FUM4basebioLON:4BBMereo BioPharma Group plc (MPH.L)LON:MPHScancellLON:SCLPView All Competitors TILS Stock Analysis - Frequently Asked Questions How were Tiziana Life Sciences' earnings last quarter? Tiziana Life Sciences PLC (LON:TILS) posted its quarterly earnings results on Wednesday, September, 30th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.00) by $1.40. What other stocks do shareholders of Tiziana Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Synergy Pharmaceuticals (SGYP), Micron Technology (MU), ServiceNow (NOW), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Broadcom (AVGO), Dropbox (DBX), Enterprise Products Partners (EPD) and Franco-Nevada (FNV). How do I buy shares of Tiziana Life Sciences? Shares of TILS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:TILS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
